Posted On: 06/30/2014 7:48:58 PM
Post# of 109
$FOLD climber. candle. $3.34
Website
O/S shares 64,340,526
10-Q 5/15/14
recent trades & Pr
StockWatch
Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012
2014-06-30 07:00 ET - News Release
Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension
Statistical Analysis Plan Finalized
Website
O/S shares 64,340,526
10-Q 5/15/14
recent trades & Pr
StockWatch
Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012
2014-06-30 07:00 ET - News Release
Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension
Statistical Analysis Plan Finalized
(0)
(0)
